These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 19809816)

  • 1. Correlation of ESR, C3, C4, anti-DNA and lupus activity based on British Isles Lupus Assessment Group Index in patients of rheumatology clinic.
    Nasiri S; Karimifar M; Bonakdar ZS; Salesi M
    Rheumatol Int; 2010 Nov; 30(12):1605-9. PubMed ID: 19809816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus.
    Yee CS; Farewell V; Isenberg DA; Rahman A; Teh LS; Griffiths B; Bruce IN; Ahmad Y; Prabu A; Akil M; McHugh N; D'Cruz D; Khamashta MA; Maddison P; Gordon C
    Arthritis Rheum; 2007 Dec; 56(12):4113-9. PubMed ID: 18050213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products.
    Lim KL; Jones AC; Brown NS; Powell RJ
    Ann Rheum Dis; 1993 Jun; 52(6):429-35. PubMed ID: 8323394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus.
    Ho A; Barr SG; Magder LS; Petri M
    Arthritis Rheum; 2001 Oct; 44(10):2350-7. PubMed ID: 11665976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4.
    Julkunen H; Ekblom-Kullberg S; Miettinen A
    Rheumatol Int; 2012 Aug; 32(8):2445-51. PubMed ID: 21706294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies to extractable nuclear antigens (ENAS) in systemic lupus erythematosus patients: correlations with clinical manifestations and disease activity.
    Emad Y; Gheita T; Darweesh H; Klooster P; Gamal R; Fathi H; El-Shaarawy N; Gamil M; Hawass M; El-Refai RM; Al-Hanafi H; Abd-Ellatif S; Ismail A; Rasker J
    Reumatismo; 2018 Jul; 70(2):85-91. PubMed ID: 29976042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus.
    Ho A; Magder LS; Barr SG; Petri M
    Arthritis Rheum; 2001 Oct; 44(10):2342-9. PubMed ID: 11665975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The model of circulating immune complexes and interleukin-6 improves the prediction of disease activity in systemic lupus erythematosus.
    Thanadetsuntorn C; Ngamjanyaporn P; Setthaudom C; Hodge K; Saengpiya N; Pisitkun P
    Sci Rep; 2018 Feb; 8(1):2620. PubMed ID: 29422675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contribution of resting heart rate and routine blood tests to the clinical assessment of disease activity in systemic lupus erythematosus.
    Guzmán J; Cardiel MH; Arce-Salinas A; Alarcón-Segovia D
    J Rheumatol; 1994 Oct; 21(10):1845-8. PubMed ID: 7837148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of methotrexate on improving serological abnormalities of patients with systemic lupus erythematosus.
    Miyawaki S; Nishiyama S; Aita T; Yoshinaga Y
    Mod Rheumatol; 2013 Jul; 23(4):659-66. PubMed ID: 23011357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of the Levels of C4d-bearing Reticulocytes and High-avidity Anti-dsDNA Antibodies with Disease Activity in Systemic Lupus Erythematosus.
    Mora C; Medina-Rosas J; Santos AM; Jaimes DA; Arbeláez AM; Romero C; Cortes A; Londono J
    J Rheumatol; 2016 Sep; 43(9):1657-64. PubMed ID: 27134246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urine neopterin: a new parameter for serial monitoring of disease activity in patients with systemic lupus erythematosus.
    Lim KL; Muir K; Powell RJ
    Ann Rheum Dis; 1994 Nov; 53(11):743-8. PubMed ID: 7826135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally.
    Yee CS; Gordon C; Isenberg DA; Griffiths B; Teh LS; Bruce IN; Ahmad Y; Rahman A; Prabu A; Akil M; McHugh N; Edwards CJ; D'Cruz D; Khamashta MA; Farewell VT
    Arthritis Care Res (Hoboken); 2022 Oct; 74(10):1623-1630. PubMed ID: 33787088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD69 to CD3 ratio of peripheral blood mononuclear cells as a marker to monitor systemic lupus erythematosus disease activity.
    Su CC; Shau WY; Wang CR; Chuang CY; Chen CY
    Lupus; 1997; 6(5):449-54. PubMed ID: 9229364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity.
    Kim AHJ; Strand V; Sen DP; Fu Q; Mathis NL; Schmidt MJ; Bruchas RR; Staten NR; Olson PK; Stiening CM; Atkinson JP
    Arthritis Rheumatol; 2019 Mar; 71(3):420-430. PubMed ID: 30294950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serum free light chains for monitoring systemic lupus erythematosus activity].
    Żychowska I; Suszek D; Dryglewska M; Nurzyńska D; Donica H; Majdan M
    Wiad Lek; 2018; 71(1 pt 1):21-31. PubMed ID: 29558348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum ferritin level correlates with SLEDAI scores and renal involvement in SLE.
    Tripathy R; Panda AK; Das BK
    Lupus; 2015 Jan; 24(1):82-9. PubMed ID: 25253568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlations between antinucleosome antibodies and anti-double-stranded DNA antibodies, C3, C4, and clinical activity in lupus patients.
    Saisoong S; Eiam-Ong S; Hanvivatvong O
    Clin Exp Rheumatol; 2006; 24(1):51-8. PubMed ID: 16539819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sub-setting systemic lupus erythematosus by combined molecular phenotypes defines divergent populations in two phase III randomized trials.
    Petri M; Watts SD; Higgs RE; Linnik MD
    Rheumatology (Oxford); 2021 Nov; 60(11):5390-5396. PubMed ID: 33580248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.